Caroline Papeix

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults

Álvaro Cobo‐Calvo, Anne Ruiz, Élisabeth Maillart et al. · Neurology · 2018 · 532 citations

Life Sciences, Neurology, Neuroscience +17

Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis

Céline Louapre, Nicolas Collongues, Bruno Stankoff et al. · JAMA Neurology · 2020 · 466 citations · Full text

Medicine, Infectious Diseases, Clinical Epidemiology +14

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study

Ayman Tourbah, Christine Lebrun‐Frénay, Gilles Edan et al. · Multiple Sclerosis Journal · 2016 · 287 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +10

Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

Álvaro Cobo‐Calvo, Anne Ruiz, Fabien Rollot et al. · Annals of Neurology · 2020 · 261 citations · Full text

Medicine, Immunology, Neurology +17